SITC 2022 | Radiomic texture patterns on CT scans as biomarker of early response to CDK4/6 inhibitors in HR+ mBC

Anant Madabhushi, PhD, Emory University School of Medicine, Atlanta, GA, discusses changes in radiomic texture patterns on CT scans as a biomarker of early response to CDK 4/6 inhibitors in HR+ metastatic breast cancer. It was demonstrated that by looking at contextual patterns of the tumor and associated tumor milieu, CT scans were strongly implicated with response, as well as clinically relevant outcomes, in patients treated with CDK4/6 inhibitors. This interview took place at the 37th Annual Meeting of the Society for Immunotherapy in Cancer (SITC 2022) in Boston, MA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.